Advertisement

Topics

Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma

06:25 EDT 15 Sep 2018 | Cancer Networks

Mogamulizumab (Poteligeo) is indicated for relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy.

Original Article: Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma

NEXT ARTICLE

More From BioPortfolio on "Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement